Outlook Therapeutics, Inc. ( OTLK ) NASDAQ Capital Market

Cena: 2.68 ( 11.0% )

Aktualizacja 08-22 21:58
NASDAQ Capital Market
Branża: Biotechnology
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Outlook Therapeutics, Inc., późna kliniczna firma biofarmaceutyczna, koncentruje się na rozwijaniu i komercjalizacji przeciwciał monoklonalnych dla różnych wskazań okulistycznych. Jego głównym kandydatem na produkt jest ONS-5010, ophthalmiczny preparat kandydata na produkt bewacyzumabu, który jest w badaniu klinicznym fazy III w celu leczenia zwyrodnienia plamki związanej z mokrem i innych chorób siatkówki. Outlook Therapeutics, Inc. ma umowy o współpracy i licencji z IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis pte. Ltd.; oraz Zhejiang Huahai Pharmaceutical Co., Ltd. Firma była wcześniej znana jako Oncobiologics, Inc. i zmieniła nazwę na Outlook Therapeutics, Inc. w listopadzie 2018 r. W listopadzie 2018 r. Outlook Therapeutics, Inc. został zarejestrowany w 2010 roku i ma siedzibę w Iselin, New Jersey.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 24
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 56.6789
Ilość akcji: Brak danych
Debiut giełdowy: 2016-06-14
WWW: https://www.outlooktherapeutics.com
CEO: Mr. C. Russell Trenary III
Adres: Building F
Siedziba: 08852 Iselin
ISIN: US69012T3059
Wskaźniki finansowe
Kapitalizacja (USD) 118 822 162
Aktywa: 47 091 727
Cena: 2.68
Wskaźnik Altman Z-Score: -15.9
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -3.2
Ilość akcji w obrocie: 57%
Średni wolumen: 1 169 519
Ilość akcji 44 419 500
Wskaźniki finansowe
Przychody TTM 0
Zobowiązania: 130 765 215
Przedział 52 tyg.: 0.87 - 8.32
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -0.8
P/E branży: 28.3
Beta: 0.63
Raport okresowy: 2025-12-18
WWW: https://www.outlooktherapeutics.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. C. Russell Trenary III President, Chief Executive Officer & Director 610 899 1958
Mr. Jeffrey Evanson Chief Commercial Officer 451 170 1969
Mr. Ralph H. Thurman Independent Executive Chairman 207 500 1949
Mr. Jedd Comiskey Senior Vice President - Head of Europe 0 0
Mr. Joel Prieve Senior Vice President of Licensing and M&A 0 0
Dr. Surendra Sharma M.D. Senior Vice President of Medical Affairs 0 0
Dr. Jennifer M. Kissner Ph.D. Senior Vice President of Clinical Development & Regulatory Affairs 0 0
Mr. Lawrence A. Kenyon CPA Executive Vice President, Chief Financial Officer, Treasurer, Company Secretary & Director 0 1966
Lista ETF z ekspozycją na akcje Outlook Therapeutics, Inc.
Symbol ETF Ilość akcji Wartość
VTI 963 411 1 541 457
IWC 49 210 96 452
Wiadomości dla Outlook Therapeutics, Inc.
Tytuł Treść Źródło Aktualizacja Link
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. globenewswire.com 2025-05-15 20:01:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD. globenewswire.com 2025-04-08 12:45:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigational ophthalmic product which, if approved, will be branded as LYTENAVA™ (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). globenewswire.com 2025-02-28 10:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference. globenewswire.com 2025-02-19 11:00:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025 LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025 ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a corporate update. globenewswire.com 2025-02-14 10:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial globenewswire.com 2025-02-04 11:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director. globenewswire.com 2025-01-31 10:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting being held January 18-24, 2025 in Kauai, HI. globenewswire.com 2025-01-23 11:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar ISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Lawrence A. globenewswire.com 2025-01-22 11:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet AMD) patients. benzinga.com 2025-01-16 14:09:50 Czytaj oryginał (ang.)
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT, the second of two adequate and well controlled clinical trials evaluating ONS-5010 in wet AMD patients. ONS-5010 demonstrated noninferiority to ranibizumab at week 12 in the NORSE EIGHT trial. Based on the completed analysis of the 12-week results, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025. globenewswire.com 2025-01-16 08:00:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD globenewswire.com 2025-01-08 11:15:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for fiscal year 2024 and provided a corporate update. globenewswire.com 2024-12-27 10:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Streamlines Operations ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that following an internal strategic review, the management team and Board of Directors have implemented initiatives to streamline the organization, reduce operating expenses and preserve capital, with the goal of maximizing its efforts to commercially launch LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) and supporting the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ to the U.S. Food and Drug Administration (FDA). globenewswire.com 2024-12-13 18:30:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000 new wet AMD patients each year in the UK who could benefit from treatment 1 ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that the National Institute for Health and Care Excellence (NICE) has recommended LYTENAVA™ (bevacizumab gamma), as an option for the treatment of wet AMD. globenewswire.com 2024-12-04 10:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Announces Executive Leadership Transition ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. globenewswire.com 2024-12-03 18:30:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com 2024-12-02 16:31:00 Czytaj oryginał (ang.)
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD. zacks.com 2024-11-28 13:31:08 Czytaj oryginał (ang.)
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients. benzinga.com 2024-11-27 11:27:39 Czytaj oryginał (ang.)
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced preliminary topline results of NORSE EIGHT, the second of two adequate and well controlled clinical trials evaluating ONS-5010 in wet AMD patients. Upon the completion of analysis of the final results of NORSE EIGHT, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) application for ONS-5010 in the first quarter of calendar 2025. globenewswire.com 2024-11-27 08:50:00 Czytaj oryginał (ang.)
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET globenewswire.com 2024-11-06 10:05:00 Czytaj oryginał (ang.)
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASDAQ: OTLK) on behalf of long-term stockholders following a class action complaint that was filed against Outlook on November 3, 2023 with a Class Period from December 29, 2022 to August 29, 2023. Our investigation concerns whether the board of directors of Outlook have breached their fiduciary duties to the company. globenewswire.com 2024-10-12 01:00:00 Czytaj oryginał (ang.)
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET globenewswire.com 2024-09-16 12:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series Webcast replay of fireside chat now available globenewswire.com 2024-09-13 13:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced the completion of enrollment for its NORSE EIGHT clinical trial evaluating ONS-5010 in wet AMD patients. NORSE EIGHT is the subject of a Special Protocol Assessment (SPA) agreement with the FDA, and, if successful, is the final anticipated clinical trial required before expected resubmission of the Outlook Therapeutics' Biologics License Application (BLA) for ONS-5010. globenewswire.com 2024-09-04 12:35:00 Czytaj oryginał (ang.)
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. globenewswire.com 2024-09-03 12:45:00 Czytaj oryginał (ang.)
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles Outlook Therapeutics faces liquidity issues and delays in FDA approval for its Wet AMD therapy, leading to a downgrade from Strong Buy to Buy. The potential blockbuster market for LYTENAVA in treating Wet AMD is significant, but FDA hurdles and financial constraints pose risks. Despite high upside potential, investors face the risk of losing their entire stake due to Outlook's financial and regulatory challenges. seekingalpha.com 2024-08-26 08:11:43 Czytaj oryginał (ang.)
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the third quarter of fiscal year 2024 and provided a corporate update. As previously announced, Outlook Therapeutics will host its quarterly conference call and live audio webcast, today, Wednesday, August 14, 2024, at 8:30 AM ET (details below). globenewswire.com 2024-08-14 11:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat at the H.C. Wainwright 4 th Annual Ophthalmology Virtual Conference being held on Thursday, August 15, 2024. globenewswire.com 2024-08-12 13:05:00 Czytaj oryginał (ang.)
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced that it will report its financial results for third quarter fiscal year 2024 on Wednesday, August 14, 2024. Outlook Therapeutics management will host its quarterly conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day. globenewswire.com 2024-08-07 12:35:00 Czytaj oryginał (ang.)
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024 Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET globenewswire.com 2024-07-30 13:10:00 Czytaj oryginał (ang.)
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume. marketbeat.com 2024-07-11 11:12:55 Czytaj oryginał (ang.)